NDA 021670 · Dorc
Visionblue
Trypan Blue · Ophthalmic
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Dec 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Dec 16, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
0 Phase 3, 1 recruiting
FAERS reports
44
43 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 17, 2026.
Indications & Usage VisionBlue® 0.06% is indicated for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens. VisionBlue® 0.06% is a diagnostic dye indicated for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens.
Mechanism: Mechanism of action VisionBlue® 0.06% selectively stains connective tissue structures in the human eye such as the anterior lens capsule of the human crystalline lens. VisionBlue® 0.06% is intended to be applied directly on the anterior lens capsule, staining any portion of the capsule which comes in contact with the dye. Excess dye is washed out of the anterior chamber. The dye does not penetrate the capsule, permitting visualization of the anterior capsule in contrast to the non-stained lens cortex and inner lens material.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 16, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelReviewLetter
1 products under this application
- VISIONBLUE · TRYPAN BLUE 0.06% · SOLUTION, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trypan Blue" as an intervention, any sponsor and status, largest first.
Hayat Abad Medical Complex, PeshawarGovernment (non-federal)
NCT07735000 · 60 participants · Start Mar 22, 2024 · Primary completion Sep 22, 2024
Drug: Trypan Blue · For: Age Related Cataract; Cataract
Sites: Peshawar, Pakistan
- Descemet Endothelial Thickness Comparison TrialStatus unknown
Oregon Health and Science UniversityAcademic, hospital or other
NCT02373137 · 38 participants · Start Jan 22, 2015 · Primary completion Apr 4, 2018
Drug: Prednisolone; Ofloxacin and 2 more · For: Keratoplasty; Grafting, Corneal; Transplantation, Corneal and 2 more
Sites: Palo Alto, California; San Francisco, California; Portland, Oregon
Centre Hospitalier Universitaire de NiceAcademic, hospital or other
NCT07813884 · 15 participants (planned) · Start Oct 1, 2026 · Primary completion Oct 1, 2027
Drug: BPR001-615 · For: Colorectal Adenocarcinoma
Sites: Nice, France
Makerere UniversityAcademic, hospital or other
NCT04553159 · 8 participants · Start Mar 1, 2021 · Primary completion Jun 16, 2021
Drug: Autologous adipose derived stem cells · For: Keloid; Autologus Adipose Derived Stem Cells; Feasibility and 1 more
Sites: Kampala, Uganda
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- toxic anterior segment syndrome24
- blindness21
- corneal oedema10
- product quality issue6
- cerebral infarction3
- endophthalmitis3
- off label use3
- pigmentation disorder3
- thyroid disorder3
- condition aggravated2
- vision blurred2
- corneal decompensation1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2014 | 21 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Analysis of success rate of organoid construction of nasopharyngeal carcinoma by first-day suspension method].
Huo HM, Yao X, Lai YJ, et al. · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2023 · Randomized Controlled Trial, English Abstract
- The role of novel DMEK graft shapes in facilitating intraoperative unscrolling.
Modabber M, Talajic JC, Mabon M, et al. · Graefes Arch Clin Exp Ophthalmol 2018 · Randomized Controlled Trial
- Use of Brilliant Blue G in Descemet's Membrane Endothelial Keratoplasty.
Hayashi T, Yuda K, Oyakawa I, et al. · Biomed Res Int 2017 · Clinical Trial, Comparative Study
- Impact of β-glucan on the Fecal Water Genotoxicity of Polypectomized Patients.
Turunen KT, Pletsa V, Georgiadis P, et al. · Nutr Cancer 2016 · Randomized Controlled Trial
- Effect of levobupivacaine on articular chondrocytes: an in-vitro investigation.
Cobo-Molinos J, Poncela-Garcia M, Marchal-Corrales JA, et al. · Eur J Anaesthesiol 2014 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Endothelial cell integrity after phacoemulsification with 2 different handpieces.
Vargas LG, Holzer MP, Solomon KD, et al. · J Cataract Refract Surg 2004 · Clinical Trial, Randomized Controlled Trial
Sponsor: Dorc
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.